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Abstract 
Objective: The genetic polymorphism (rs16969968 in CHRNA5, and rs1051730 in CHRNA3 genes) were recently 
shown to be associated with risk of LC. The aim of this study is to elucidate whether they predispose Palestinian indi‑
viduals to lung cancer, and how is this related to smoking.
Results: Frequency of the rs16969968‑A allele was significantly higher in the case group (36.7%) than in normal con‑
trols (17.5%; P = 0.022; OR = 6.83 for AA and 2.81 for AG genotypes). The frequency of rs1051730‑T allele was also sig‑
nificantly higher in the case group (46.7%) than in the control group (22.5%; P = 0.001; OR = 2.20 for TC and 13.22 for 
TT genotypes). Frequency of rs16969968‑A allele was higher in smokers (29.1%) than nonsmokers (15.7%) regardless 
of lung cancer; similarly, frequency of rs1051730‑T allele was also higher in smokers than in smokers (46.7% vs 22.5%, 
respectively). The higher the proportion of the risk allele (rs16969968‑A and rs1051730‑T), the higher the mean num‑
ber of daily consumed cigarettes (P = 0.006). Carrying rs16969968‑A and/or rs1051730‑T alleles results in an increased 
risk to lung cancer probably by increasing the individual’s tendency for heavy smoking. The allelic frequency of the 
rs16969968‑A and rs1051730‑T alleles among normal Palestinian controls is similar to different populations worldwide.
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Introduction
Lung cancer (LC) has been, for decades, the leading 
cause of male cancer related death both in developing 
and developed countries [1]. Recently, it has surpassed 
breast cancer as the leading cause of cancer death in 
females in developed countries, probably because of the 
lately spread of tobacco epidemic in females [2]. Both 
active and passive smoking are well known risk factors 
for lung cancer [3–9]. Between 80 and 90% of lung can-
cer are attributed to smoking [10, 11]. Nevertheless, the 
majority of smokers don’t develop LC during their life, 
most likely as a result of genetic polymorphism. Research 
has pointed the role of the person’s genetic makeup in 
growing his/her likelihood of becoming attached to ciga-
rettes as well as in increasing susceptibility to lung cancer 
[12–15]. Independent genome-wide association studies 
(GWAS) identified two single nucleotide polymorphisms 
(SNPs) in the genes for nicotinic acetylcholine receptor 
(rs16969968 in CHRNA5, and rs1051730 in CHRNA3 
genes) to be consistently associated with risk of LC [16, 
17]. Those polymorphisms are most likely increasing the 
risk of LC via increasing the individual’s dependence to 
nicotine [18–22].
About 22.5% of Palestinian individuals (≥ 18  years) 
are smokers [23]. LC is overall the third leading cause of 
death (9.8% of reported cases), and is one of the major 
causes of morbidity among Palestinian population [24]. 
Therefore, in this study we aimed at determining the 
frequency of the SNPs (rs16969968 in CHRNA5, and 
rs1051730 in CHRNA3) and elucidating their possi-
ble role in risk for nicotine dependence and lung cancer 
among the Palestinian population.
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The present study is a case control study with con-
venience sample. Cases were recruited from all LC 
patients managed in the oncology departments of Al-
Shifa Hospital (n = 17) and European Gaza Hospital 
(n = 13) during the period from February 2014 to June 
2014. Patients were excluded if their LC was a metas-
tasis originating from other organs. The diagnosis of 
lung cancer was previously confirmed by the diagnostic 
tools available in the managing hospitals. The major-
ity of cases were males (93.3% males and 6.7% females). 
The mean age of lung cancer cases was 61.4 ± 9.1 years 
(range 45–80 years).
The control group comprised 60 participants (30 
smoker and 30 nonsmokers) matched to the cases 
in gender (71.7% males and 8.3% females) and age 
(mean = 60.4 ± 7.9 years; range 43–80 years).
Sample collection and genomic DNA extraction
About 5  ml peripheral blood were collected from each 
case and control in EDTA-anti-coagulated vacutainers. 
Genomic DNA was extracted from peripheral lympho-
cytes using the QIAamp DNA Blood Mini kit (Qiagen, 
Germany) according to the manufacturer instructions.
Genotype determination with allele‑specific primer (ASP) PCR
Allele-specific (AS) primers (Additional file  1) were 
designed using the Web-based Allele-Specific PCR 
assay (WASP) online software [25] and purchased from 
(Hylabs, Israel). Additional mismatches were intention-
ally introduced at the penultimate base of the AS primers 
to increase specificity as described earlier [26].
Two separate 20  μl-reactions were performed for 
each SNP, one for the wild-type allele and the second 
for the variant allele. All amplifications were carried out 
in the presence of 1× GoTaq Green Master Mix (Pro-
mega, USA), 50  ng genomic DNA, 0.5  µM common 
sense primer and 0.5  µM wild-type specific antisense 
or mutant-specific primers. The temperature profile for 
the SNP: rs16969968 included an initial denaturation at 
95 °C for 5 min, followed with 38 cycles of 95 °C for 30 s, 
58 °C for 30 s and 72 °C for 45 s. A final 10 min extension 
step was performed at 72 °C. The temperature profile for 
the SNP: rs1051730 was the same except for  annealing 
temperature which was performed at 59  °C for 30  s. To 
validate the results, 10% randomly selected samples were 
re-genotyped and the results were concordant.
The amplification products were resolved by 2% aga-
rose gel at 100 V for 50 min in 1× TBE buffer. The gels 
were stained with 0.5  μg/µl ethidium bromide and UV-
visualized in a gel documentation system.
Data analysis
Data were collected from the patients including their age, 
gender, smoking status, number of cigarettes per day, 
type of cancer, years of smoking, period of quit smoking 
and others. The data was analyzed by the Statistical Pack-
age for the Social Sciences (SPSS; version 19). The student 
t test was applied to detect significant mean differences 
and the Pearson’s χ2 test to detect distribution differences 
of categorical variables. Statistical significance was set 
at a threshold of P = 0.05 or less. The Hardy–Weinberg 
equilibrium was examined for the distribution of geno-
types in each group using a goodness of fit χ2 test.
Results
ASP‑PCR genotyping
The ninety subjects enrolled in the study were successfully 
genotyped for the rs16969968 and rs1051730 by allele-
specific primers PCR (Fig.  1). Repeated genotyping of a 
number of samples consistently gave concordant results.
Distribution of CHRNA5 (c.1192G > A)/rs16969968
The distribution of cases and controls by genotype of 
rs16969968 is shown in (Additional file  2). The alleles 
are in Hardy–Weinberg equilibrium (P = 0.6165), and 
the overall frequency of rs16969968-A is calculated to 
be 23.9% (Additional file 2). It is higher in the case group 
(36.7%) than in the control group (17.5%). Distribution 
of the genotypes among cases and controls is statisti-
cally significant (P = 0.022). Frequency of rs16969968-
AA homozygotes and rs16969968-GA heterozygotes is 
higher in cases than in controls. Homozygosity and het-
erozygosity for the minor allele increases susceptibility 
to lung cancer when compared to the wild type genotype 
(OR = 6.83 and 2.81, respectively; Additional file 3).
Table 1 Effect of minor alleles on smoking dependence
Genotype No. cigarettes/day 
(mean ± SD)
P value
CHRNA5 (c.1192G > A) rs16969968
 GG 25.54 ± 11.6 0.006
 GA 36.04 ± 12.2
 AA 40.0 ± 15.81
CHRNA3 (c.65C > T) rs1051730
 CC 24.86 ± 12.97 0.006
 CT 33.00 ± 10.36
 TT 39.17 ± 15.62
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Distribution of CHRNA3 (c.65C > T)/rs1051730
Alleles of rs1051730 are also in Hardy–Weinberg equilib-
rium (P = 0.887). The overall frequency of rs16969968-T 
allele is 31.1% (Additional file  2). The allelic frequency 
of the susceptibility allele is higher in the case group 
(46.7%) than in the control group (22.5%). Frequency of 
the rs1051730-TT and rs1051730-CT genotypes is sig-
nificantly higher in cases than in controls (P = 0.001; 
Additional file 2). Carriage of the rs1051730-T allele in a 
homozygous or heterozygous genotype increases the risk 
for lung cancer when compared to the wild type geno-
type (OR = 3.05; Additional file 3).
Smoking status
Only four lung cancer cases were nonsmoker cases, 
while the rest 26 were smokers. Few patients have quit-
ted smoking after being diagnosed and thus were con-
sidered smokers. The amount of cigarettes smoked 
per day by lung cancer patients and smoker controls 
was not significantly different (P = 0.823; Additional 
file  4). On the other hand, the average period of smok-
ing was found to be significantly higher in lung cancer 
cases (39.04 ± 12.7  years) compared to smoker controls 
(28.0 ± 10.5 years) (P = 0.001; Additional file 4).
Relationship between smoking and genotype in lung cancer
Differences in distribution of the rs16969968 genotypes 
between the smoker cases and smoker controls was not 
statistically significant (P = 0.272; Additional file  5). 
Analysis of statistical significance could not be applied to 
compare non-smoker case (n = 4) and non-smoker con-
trol (n = 30) because of the small sample size. The allelic 
frequency of the rs16969968-A allele is higher in smok-
ers (29.1%) than nonsmokers (15.7%), regardless of lung 
cancer.
On the other hand, differences in distribution of the 
rs1051730 genotypes between smoker cases and smoker 
controls was statistically significant (P = 0.015; Addi-
tional file 5). Frequency of rs1051730-T allele is higher in 
smokers (26.6%) than nonsmokers (18.3%). regardless of 
lung cancer.
Table  1 shows that the higher the proportion of 
rs16969968-A allele or rs1051730-T allele, the higher the 
mean number of daily consumed cigarettes (P = 0.006 for 
both alleles).
The average duration of smoking was not significantly 
different between the different genotypes of rs16969968 
and rs1051730 genotypes (P = 0.402 and 0.320, respec-
tively; Table 2).
Discussion
In this study, we have developed and applied an ASP-PCR 
technique for genotyping the rs16969968 and rs1051730 
SNPs at the CHRNA5/CHRNA3 locus. The worldwide 
frequency of rs16969968-A allele ranges from 1% in cer-
tain populations such as African and Japanese to more 
than 47% in others such as European populations [27]. 
The frequency in our normal control individuals falls in 
the middle 17.5%. The rs16969968-A allele frequency 
is higher in the case group (36.7%). The distribution of 
rs16969968 genotypes among cases and controls is sta-
tistically significant (P = 0.022), supporting the poten-
tial role of rs16969968-A in risk of LC (OR = 6.83 for 
rs16969968-AA and OR = 2.81 for rs16969968-AG). Like 
previously reported data, this allele may be predisposing 
to LC independently from smoking [28–30].
The allelic frequency for the T-allele of the SNP 
rs1051730 in the control group is 22.5%. The overall 
Fig. 1 A representative agarose gel electrophoresis of ASP‑PCR. a 
The SNP rs16969968 and b the SNP rs1051730 were genotyped with 
two separate reactions for each sample: one using wildtype‑specific 
primer (wt) and the other using mutant‑specific primers (mt). L 
100 bp DNA ladder and B blank water sample. Samples (S30, S31, 
and S33) are wildtype homozygous and sample S32 is heterozygous 
for both SNPs
Table 2 Effect of genotype on mean smoking duration
Duration (years) mean ± SD P value
CHRNA5 (c.1192G > A) rs16969968
 GG 35.4 ± 12.4 0.402
 GA 30.6 ± 13.6
 AA 31.8 ± 10.7
CHRNA3 (c.65C > T) rs1051730
 CC 35.8 ± 13.1 0.320
 CT 30.6 ± 12.9
 TT 35.8 ± 10.3
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worldwide frequency of rs1051730-T allele is 16.8%, 
ranging from 2.7% in east Asia to 47.7% in Iberian pop-
ulation of Spain [27]. Similar to rs16969968, frequency 
of rs1051730-T allele is higher in the case group, and 
the distribution of rs1051730 genotypes between cases 
and controls is statistically significant (P = 0.001). The 
rs1051730-TC and -TT genotypes seem to confer the 
individual susceptible to LC (OR = 2.20 and 13.22, 
respectively). These findings are parallel to previously 
published data which demonstrated that rs1051730-T 
allele is risk-conferring for the development of lung can-
cer in different ethnic groups [31–34]. These data also 
suggest an independent role for rs1051730-T allele in 
predisposition to lung cancer apart from smoking. The 
rs1051730 polymorphism was suggested to modify sus-
ceptibility to lung cancer among Chinese Han population 
by a smoking-independent manner [35, 36]. It was also 
suggested to function as a genetic modifier for the risk of 
developing lung adenocarcinoma in nonsmoking Chinese 
females [37].
The postulation that both SNPs increase the risk of 
LC independently from smoking comes from Additional 
file 4, in which the mean number of daily consumed ciga-
rettes was not significantly different between the smoker 
cases and smoker controls (P = 0.823). Rather, the dura-
tion of smoking was far more important in predicting 
lung cancer risk (P = 0.001; Additional file 4) [38–40]. In 
this regard, Table 2 shows that the genotype of both SNPs 
does not significantly influence the duration of smoking.
The allelic frequency of rs16969968-A and rs1051730-T 
susceptibility alleles was calculated in smokers and non-
smokers regardless of LC. The frequency of rs16969968-
A allele was higher in smokers (29.1%) than nonsmokers 
(15.7%). The frequency of rs1051730-T allele was also 
higher in smokers than in smokers (46.7% vs. 22.5%, 
respectively). Furthermore, Table  1 shows that the 
higher the proportion of the risk allele (rs16969968-A 
and rs1051730-T), the higher the mean number of daily 
consumed cigarettes (P = 0.006). Accordingly, we may 
consider homo- or heterozygosity for the rs16969968-
A and rs1051730-T allele predisposing for smoking 
dependence. In support of this assumption, carriers of 
the rs16969968-A allele were reported to have signifi-
cantly higher serum nicotine levels, and to correlate with 
Fagerström test results for Nicotine Dependence [41]. 
Furthermore, higher smoking intensity was reported in 
rs1051730-CT heterozygote and rs1051730-TT homozy-
gote smokers compared with wild-type smokers [42, 43].
Tobacco smoking increases the risk of at least 17 
classes of human cancer probably by increasing the 
somatic mutation load [44]. Nicotine and other tobacco 
components may contribute to lung cancer by modifying 
the gene expression to induce epithelial to mesenchymal 
transition (EMT) [45–47]. Nicotine can also contribute 
to proliferation in LC through the activation of nicotinic 
acetylcholine receptors (nAChRs) [48]. Therefore, we may 
conclude that each of the rs16969968-A and rs1051730-T 
alleles increases the individual’s dependence on tobacco 
smoking, which in turn confers him/her susceptible to 
LC. This conclusion supports previously reported asso-
ciation of rs16969968-A with LC risk largely via tobacco 
exposure [22, 49–51]. Lips, and colleagues demonstrated 
that association between rs16969968-A and LC risk was 
unchanged after adjusting for smoking (OR = 1.30 VS 
smoking adjusted OR = 1.27) [52]. Similar to our results, 
an increased nicotine level indicates an increased risk 
of LC with each additional copy of the rs1051730 and 
rs16969968 risk allele [51, 53, 54]. A recent meta-analysis 
concluded that the rs16969968-A predicts delayed smok-
ing cessation and an earlier age of lung cancer diagnosis 
[55].
In conclusion, carrying one or the other of the risk 
alleles rs16969968-A and rs1051730-T results in an 
increased risk to lung cancer probably by increasing 
the individual’s tendency to smoke more and at an ear-
lier age. The allelic frequency of the rs16969968-A and 
rs1051730-T alleles among normal Palestinian controls 
falls within the worldwide range in different populations.
Limitations
The main limitation of the present study is the small 
sample size, which limited our ability to detect moderate 
interactions especially in the stratified analyses. Larger 
studies are needed in the future to confirm our findings 
in the Palestinian population. In addition, lack of infor-
mation and absence of properly organized patient record 
at the managing hospital limited access to the patients.
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